Cargando…

Ustekinumab Exposure in Pregnant Women From Inflammatory Bowel Disease Clinical Trials: Pregnancy Outcomes Through Up To 5 Years in Crohn’s Disease and 2 Years in Ulcerative Colitis

BACKGROUND: While no adverse developmental outcomes were observed in preclinical animal studies, limited data exist regarding effects of ustekinumab on human pregnancies. Previously, no data have been reported for women treated with ustekinumab in inflammatory bowel disease (IBD) clinical trials and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abraham, Bincy P, Ott, Elyssa, Busse, Christopher, Murphy, Conor, Miller, Lindsay, Baumgart, Daniel C, Scherl, Ellen, Gasink, Christopher
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Observations and Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802371/ https://www.ncbi.nlm.nih.gov/pubmed/36777422 http://dx.doi.org/10.1093/crocol/otac025

Ejemplares similares

Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs
por: Ghosh, Subrata, et al.
Publicado: (2019)

Effectiveness and Durability of Ustekinumab Therapy With or Without Immunomodulators for Ulcerative Colitis Patients in Japan
por: Aoki, Yasuhiro, et al.
Publicado: (2022)

Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs
por: Ghosh, Subrata, et al.
Publicado: (2019)

Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy
por: Sandborn, W. J., et al.
Publicado: (2018)

Long-Term Clinical Effectiveness of Ustekinumab in Patients With Crohn’s Disease: A Retrospective Cohort Study
por: Ito, Takahiro, et al.
Publicado: (2020)

Real-World Effectiveness and Safety of Ustekinumab for Ulcerative Colitis From 2 Tertiary IBD Centers in the United States
por: Hong, Simon J, et al.
Publicado: (2021)

A Single Center Experience With Long-Term Ustekinumab Use and Reinduction in Patients With Refractory Crohn Disease
por: Bennett, Audrey, et al.
Publicado: (2020)

Safety and Effectiveness of Ustekinumab for Crohn’s Disease in Japanese Post-marketing Surveillance in Biologic-Naive and -Experienced Conriemed
por: Nagano, Katsumasa, et al.
Publicado: (2023)

Serum Ustekinumab Concentrations Are Associated With Remission in Crohn’s Disease Defined by a Serum-Based Endoscopic Healing Index
por: Walshe, Margaret, et al.
Publicado: (2021)

Clinical utility of ustekinumab in Crohn’s disease
por: Kotze, Paulo Gustavo, et al.
Publicado: (2018)

Rectal Urgency Among Patients With Ulcerative Colitis or Crohn’s Disease: Analyses from a Global Survey
por: Ha, Christina, et al.
Publicado: (2023)

Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension
por: Abreu, Maria T, et al.
Publicado: (2022)

Case Series: Re-induction of Intravenous, Weight-Based Ustekinumab Is Well Tolerated in Patients With Moderate–Severe Crohn’s Disease
por: Lee, Scott David, et al.
Publicado: (2022)

Patient-Preferences Favoring Treatment Discontinuation Are Reduced With Vedolizumab and Ustekinumab Compared With TNF Antagonists in Inflammatory Bowel Disease
por: Kumar, Anand, et al.
Publicado: (2020)

Inflammatory Response in Patients With Crohn’s Disease Compared With Ulcerative Colitis: Secondary Results of a Prospective Pilot Study
por: El-Hussuna, Alaa, et al.
Publicado: (2022)

Work-Related Productivity Loss and Associated Indirect Costs in Patients With Crohn’s Disease or Ulcerative Colitis in the United States
por: Ding, Zhijie, et al.
Publicado: (2022)

Persistence and Dose Escalation During Maintenance Phase and Use of Nonbiologic Medications Among Patients With Ulcerative Colitis Initiated on Ustekinumab in the United States
por: Zhdanava, Maryia, et al.
Publicado: (2023)

Questionnaire Survey for Inflammatory Bowel Disease Patients in Japan; A Web-Based Japan, Crohn’s Disease, Ulcerative Colitis, Patients Survey
por: Matsumoto, Takayuki, et al.
Publicado: (2023)

Patients' perspectives on smoking and inflammatory bowel disease: An online survey in collaboration with European Federation of Crohn's and Ulcerative Colitis Associations
por: Le Berre, Catherine, et al.
Publicado: (2020)

Clinical Outcome Assessments in Pediatric Patients With Ulcerative Colitis and Crohn’s Disease Receiving Biologics: A Retrospective Cohort Study
por: Hunter, Theresa, et al.
Publicado: (2022)

Extraintestinal Manifestations and Other Comorbidities in Ulcerative Colitis and Crohn Disease: A Danish Nationwide Registry Study 2003–2016
por: Vadstrup, Kasper, et al.
Publicado: (2020)

Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies
por: Hibi, Toshifumi, et al.
Publicado: (2017)

Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies
por: Sandborn, William J, et al.
Publicado: (2020)

MicroRNA signatures differentiate Crohn’s disease from ulcerative colitis
por: Schaefer, Jeremy S, et al.
Publicado: (2015)

The Impact of Confounders on Symptom–Endoscopic Discordances in Crohn’s Disease
por: Rajan, Anjana, et al.
Publicado: (2023)

Prevalence and Factors Associated With Fecal Urgency Among Patients With Ulcerative Colitis and Crohn’s Disease in the Study of a Prospective Adult Research Cohort With Inflammatory Bowel Disease
por: Dawwas, Ghadeer K, et al.
Publicado: (2021)

Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn’s Disease: Post Hoc Analyses of VISIBLE Studies
por: Sandborn, William J, et al.
Publicado: (2023)

Real-World Long-Term Remission Maintenance for 10 Years With Thiopurines in Ulcerative Colitis
por: Matsumoto, Satohiro, et al.
Publicado: (2021)

Impact of adalimumab on disease burden in moderate-to-severe ulcerative colitis patients: The one-year, real-world UCanADA study
por: Bessissow, Talat, et al.
Publicado: (2022)

Correlation of endoscopic disease severity with pediatric ulcerative colitis activity index score in children and young adults with ulcerative colitis
por: Kerur, Basavaraj, et al.
Publicado: (2017)

A Clinical Predictive Model for One-year Colectomy in Adults Hospitalized for Severe Ulcerative Colitis
por: Zafer, Maryam, et al.
Publicado: (2021)

Hypersensitivity to IV Ustekinumab but Tolerance to Subcutaneous Ustekinumab in a Patient With Crohn's Disease
por: Krugliak Cleveland, Noa, et al.
Publicado: (2020)

Combining Cyclosporine With Ustekinumab in Acute Severe Ulcerative Colitis
por: Shaffer, Seth R., et al.
Publicado: (2021)

Rapid Resolution of Vulvar Crohn's Disease With Ustekinumab
por: Stoleru, Gianna, et al.
Publicado: (2020)

Successful Treatment of Oral Crohn’s Disease by Ustekinumab
por: Jukema, Jelmer B, et al.
Publicado: (2020)

Risk of Cancer in Patients With Crohn’s Disease 30 Years After Diagnosis (the IBSEN Study)
por: Follin-Arbelet, Benoit, et al.
Publicado: (2023)

T.06.5 ONE YEAR OF USTEKINUMAB THERAPY IMPROVES NUTRITIONAL STATUS IN PATIENTS WITH CROHN’S DISEASE
por: Bertani, L., et al.
Publicado: (2022)

Rapid Induction and Maintenance of Remission in Refractory Ulcerative Colitis with Ustekinumab
por: Chen, An-Yu, et al.
Publicado: (2019)

Ustekinumab in ulcerative colitis‐ insights from the real‐world data
por: Veisman, Ido, et al.
Publicado: (2022)

Diffuse Panbronchiolitis in a Patient With Ulcerative Colitis Treated With Ustekinumab
por: Marmor, Meghan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_aq6be9qn393qi276r488e09jm8